Skip to content

Cohort Study of Chronic Obstructive Pulmonary Disease

Cohort Study of Chronic Obstructive Pulmonary Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038700
Enrollment
Unknown
Registered
2020-09-29
Start date
2020-10-20
Completion date
Unknown
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary, COPD

Interventions

COPD cohort:Follow up

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-75 years old; 2. Meet one of the following conditions: 1) FEV1/FVC =0.7 after application of bronchodilator; 3. Subjects must sign an informed consent form before participating in the study, and be able to participate in the study according to the plan and follow up for 5 years.

Exclusion criteria

Exclusion criteria: 1. Acute exacerbation in the past 3 months; 2. Suffer from other obvious lung tissue-destructive diseases, such as severe bronchiectasis and tuberculosis; 3. Suffer from severe pleural disease and/or sternum and rib disease; 4. Suffer from serious uncontrolled other system diseases; 5. Chest surgery or abdominal surgery in the past 3 months; 6. Eye surgery or retinal detachment in the past 3 months; 7. Myocardial infarction and/or hospitalization due to heart disease in the past 3 months; 8. ongoing anti-tuberculosis treatment; 9. During pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
Observe disease outcome and identify subgroups of COPD patients;

Secondary

MeasureTime frame
Identify risk factors for high-risk groups (GOLD 0) to progress to COPD;Times and severity of acute exacerbation of COPD during treatment;Blood immune indicators: Proteoglycan 4 (PRG4), C-reactive protein (CRP), serum amyloid A (SAA), procalcitonin (PCT), matrix metalloproteinases MMP-8, matrix metalloproteinases MMP -9;Pulmonary Surfactant Related Protein D (SP-D);Serum inflammatory factors: TNF-a, IL-8, IL-6, IL-2, GM-CSF;Induced sputum inflammation indicators: IL-1b, IL-8, IL-6, TNF-a, MPO and induced sputum cell count;PBMC, D-dimer (D-D), fibrinogen (FIB);Urinary Leukotriene B4 (LTB4);Exhaled nitric oxide (FeNO);Lung function test;CT scan;6-minute walk test;

Countries

China

Contacts

Public ContactDongxing Zhao

The First Affiliated Hospital Of Guangzhou Medical University

rieast@163.com+86 13650901411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026